ro7200220
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jul 22, 2019 (NCT06771271)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-6 receptor alpha subunitANTAGONIST
IL6R antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05642325 | Phase 3 | Dec 31, 2022 | Roche |
| NCT05642312 | Phase 3 | Dec 30, 2022 | Roche |
| NCT05151731 | Phase 2 | Dec 15, 2021 | Roche |
| NCT05151744 | Phase 2 | Dec 15, 2021 | Roche |
| NCT06771271 | Phase 1 | Jul 22, 2019 | Roche |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 5 | 5 | 3 | 2019 |
1 organizations
Page 1 / 1